DNAprint Genomics (DNAG)

[mjam]

Mike - I don't mean to be facetious. Doug's reply is right on target. The acquisition, partnership, merger or whatever form the drug company would take must involve existing drugs already in or entering phase III in order to meet the timeline as communicated by Tony to us in Austin and in TWST.

Whether the drug(s) are in the statin class or not is one question to ponder, but I'm being greedy when I bring that in to play. My impression is that there are small to mid range companies out there that fit this bill (having drugs that would benefit from our science to improve response rate and already in late phase II or early phase III). At one time we discussed trying to find out which companies these are (couldn't be too hard for the astute DD crew here).

Would these drugs be partnered with a test kit from DNAP or would they be altered? Are these drugs generic versions of drugs that have lost patent protection or are they new? I think these are very interesting questions.

A lot of this we hashed out several months ago. I'll go back and check some of my old posts when the next happy hour hits and I can act like a full fledged member.